⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 18, 2010Journal of Antimicrobial ChemotherapyOpen Access

Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function

Hongtao Xu Maxwel C. Oliveira Yudong Quan Tamara Bar-Magen Mark A. Wainberg

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

These properties help to explain differences in the evolution and prevalence of these two NNRTI mutations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xu et al. (2010) studied this question.

synapsesocial.com/papers/69db1aef4a1e15904c836d47 https://doi.org/10.1093/jac/dkq338

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1HIV Resistance to Nevirapine and Other Non-Nucleoside Reverse Transcriptase InhibitorsOriginal Research · 2003 · 59 citations
2Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation AgentsClinical Guideline · 2009 · 83 citations
3Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 VariantsOriginal Research · 2004 · 517 citations
4Etravirine, a Next‐Generation Nonnucleoside Reverse‐Transcriptase InhbitorOriginal Research · 2009 · 59 citations
5Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug DesignOriginal Research · 2010 · 233 citations

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues2008
TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments2005
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies2010
No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studiesJournal of Antimicrobial Chemotherapy · 2026
Phylogenetic diversification of the PoxtA ribosomal protection determinantJournal of Antimicrobial Chemotherapy · 2026

More from Journal of Antimicrobial Chemotherapy

More from McGill University

More from Jewish General Hospital